# Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome

> **NCT00466843** · PHASE2 · UNKNOWN · sponsor: **Office of Rare Diseases (ORD)** · enrollment: 54 (estimated)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Antithymocyte globulin (ATG)
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00466843
- **Lead sponsor:** Office of Rare Diseases (ORD)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-04
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2009-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00466843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00466843, "Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00466843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*